In this issue:
VEHICLES MATTER: DESIGNED FOR PURPOSE
There are several oral JAK formulations available in the United States market. The first topical cream formulation of a JAK inhibitor is ruxolitinib cream 1.5%, which is approved for the management of nonsegmental vitiligo and short-term non-continuous use for mild to moderate atopic dermatitis in adults and children 12 or older. Current guidelines of care for the management of atopic dermatitis from the American Academy of Dermatology give a strong recommendation for ruxolitinib cream for adults with AD.
Read the article here
Appraisal of Ruxolitinib 1.5% Cream as a First-Line Topical Therapeutic Agent for Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis
Dermatology has entered the long-awaited paradigm shift from steroidal to non-steroidal therapeutics for the topical treatment of atopic dermatitis. Topical Janus kinase (JAK) inhibitors have garnered a strong recommendation for the treatment of adult atopic dermatitis (AD) by the American Academy of Dermatology in the most recent updated guidelines as of 2023.
Read the article here
Ruxolitinib 1.5% Cream and the “Boxed Warning Paradoxâ€: Reappraisal of Safety Through the Lens of Pharmacokinetics
Ruxolitinib 1.5% cream is the first-in-class topical Janus kinase (JAK) inhibitor approved for the treatment of atopic dermatitis in patients 12 years of age and older. The US Food and Drug Administration (FDA) issued a “boxed warning†for ruxolitinib cream, cautioning about increased risks of serious infections, malignancies, blood clots, and cardiovascular events because it is a JAK inhibitor.
Read the article here
VEHICLES MATTER: DESIGNED FOR PURPOSE
There are several oral JAK formulations available in the United States market. The first topical cream formulation of a JAK inhibitor is ruxolitinib cream 1.5%, which is approved for the management of nonsegmental vitiligo and short-term non-continuous use for mild to moderate atopic dermatitis in adults and children 12 or older. Current guidelines of care for the management of atopic dermatitis from the American Academy of Dermatology give a strong recommendation for ruxolitinib cream for adults with AD.
Read the article here
Appraisal of Ruxolitinib 1.5% Cream as a First-Line Topical Therapeutic Agent for Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis
Dermatology has entered the long-awaited paradigm shift from steroidal to non-steroidal therapeutics for the topical treatment of atopic dermatitis. Topical Janus kinase (JAK) inhibitors have garnered a strong recommendation for the treatment of adult atopic dermatitis (AD) by the American Academy of Dermatology in the most recent updated guidelines as of 2023.
Read the article here
Ruxolitinib 1.5% Cream and the “Boxed Warning Paradoxâ€: Reappraisal of Safety Through the Lens of Pharmacokinetics
Ruxolitinib 1.5% cream is the first-in-class topical Janus kinase (JAK) inhibitor approved for the treatment of atopic dermatitis in patients 12 years of age and older. The US Food and Drug Administration (FDA) issued a “boxed warning†for ruxolitinib cream, cautioning about increased risks of serious infections, malignancies, blood clots, and cardiovascular events because it is a JAK inhibitor.
Read the article here
